Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

San Francisco Aims To Become Primary Gateway For Chinese Biotech Firms Expanding Across Pacific

This article was originally published in PharmAsia News

Executive Summary

BEIJING - San Francisco is stepping up its drive to become the North American headquarters for Chinese enterprises expanding across the Pacific and to attract life science firms based in the People's Republic to the Bay Area

You may also be interested in...



U.S. Economic Crisis, Beijing’s Perks, Could Trigger Reverse Brain Drain

BEIJING - The financial meltdown and widening layoffs in the United States, combined with Beijing's injection of stimulus funds into its pharmaceutical and biotech sectors, could trigger a reverse brain drain in those sectors, according to industry insiders and investors in the U.S. and China

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest News
See All
UsernamePublicRestriction

Register

SC070631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel